Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.However, it is a great pity that the China stock market has never had a history of retail investors and institutions getting rich together. Don't deal with hot money and quantification! Foreign investment in A-shares has also become stale and has become fond of speculation. There are always too many routines to create A shares, which is too tiring to play, and the experience is really bad.
Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.True Vision: The controlling shareholder and others intend to reduce their holdings by 4% in total;
Yiming Food issued a suggestive announcement on the risk of stock trading. Since November 26, 2024, the company's stock has been trading daily for 11 consecutive times, with a cumulative turnover rate of 66.9%, which is a risk of a sharp decline in the short term. At the same time, several major shareholders reduced their holdings of shares not exceeding 1% of the total share capital. As of the close of December 10, 2024, the three partnership platforms reduced their holdings by 138,200 shares today.Guoxin Technology: shareholders such as the National Fund intend to reduce their holdings by no more than 3%;Wentai Technology: Shareholders plan to reduce their holdings by no more than 2%;